Philips teams up with Molecular decision support leader N-of-One to speed up clinical interpretation of cancer genomics

  • Posted by Emily Haynes
  • On November 11, 2016
  • 0 Comments
Alliance aims to fortify precision medicine oncology decision support for clinicians Philips IntelliSpace Genomics solution leverages N-of-One’s extensive and variant database and interpretation solutions to extend the reach and scale of personalized medicine Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, and N-of-One, Inc., the leader in […]
Read More

med fusion Selects N-of-One to Provide Integrated Interpretation for med fusion’s New Hematologic Neoplasm Profiles

  • Posted by Emily Haynes
  • On November 8, 2016
  • 0 Comments
CONCORD, Mass., November 8, 2016 – N-of-One, Inc., a market leader in clinical interpretation with clinical trial matching for molecular tests, today announced that med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, has selected N-of-One to provide integrated interpretation of med fusion’s new HemeSEQ™ profiles for AML, CLL, DLBCL and MPN diseases. MDS […]
Read More

Inivata and N-of-One Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients

  • Posted by Emily Haynes
  • On November 3, 2016
  • 0 Comments
N-of-One to Identify Treatment Strategies and Clinical Trial Opportunities for Patients based on Inivata’s ctDNA Liquid Biopsy Analysis Research Triangle Park, NC/Cambridge, England and Concord, Mass., November 3, 2016 – Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, […]
Read More
BACK TO
TOP
LEARN
MORE